Effect of the p53 Codon 72 and Intron 3Polymorphisms on Non-Small Cell Lung Cancer (NSCLC) Prognosis

REFERENCES

• Olivier M., Eeles R., Hollstein M., Khan M. A., Harris C. C., Hainaut P. The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum. Mutat. 2002; 19: 607–614, (Version R11, up-dated October 2006)
   PubMed Web of Science ®Google Scholar
• Matlashewski G. J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L. V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell Biol. 1987; 7: 961–963
   PubMed Web of Science ®Google Scholar
• Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I. M., Matlashewski G., Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393(6682)229–234
   PubMed Web of Science ®Google Scholar
• Dumont P., Leu J. I., Della Pietra A. C., George D. L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003; 33(3)357–365
   PubMed Web of Science ®Google Scholar
• Weston A., Pan C. F., Ksieski H. B., Wallenstein S., Berkowitz G. S., Tartter P. I., Bleiweiss I. J., Brower S. T., Senie R. T., Wolff M. S. p53 haplotype determination in breast cancer. Cancer Epidemiol. Biomarkers Prev. 1997; 6(2)105–112
   PubMed Web of Science ®Google Scholar
• Powell B. L., van Staveren I. L., Roosken P., Grieu F., Berns E. M., Iacopetta B. Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 2002; 23(2)311–315
   PubMed Web of Science ®Google Scholar
• Wang-Gohrke S., Becher H., Kreienberg R., Runnebaum I. B., Chang-Claude J. Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 2002; 12(3)269–272
   PubMedGoogle Scholar
• Runnebaum I. B., Tong X. W., Konig R., Zhao H., Körner K., Atkinson E. N., Kreienberg R., Kieback D. G., Hong Z. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet 1995; 345(8955)994
   PubMed Web of Science ®Google Scholar
• Wang-Gohrke S., Weikel W., Risch H., Vesprini D., Abrahamson J., Lerman C., Godwin A., Moslehi R., Olipade O., Brunet J. S., Stickeler E., Kieback D. G., Kreienberg R., Weber B., Narod S. A., Runnebaum I. B. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br. J. Cancer 1999; 81(1)179–183
   PubMed Web of Science ®Google Scholar
• Gemignani F., Moreno V., Landi S., Moullan N., Chabrier A., Gutiérrez-Enríquez S., Hall J., Guino E., Peinado M. A., Capella G., Canzian F. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004; 23(10)1954–1956
   PubMed Web of Science ®Google Scholar
• Wu X., Zhao H., Amos C. I., Shete S., Makan N., Hong W. K., Kadlubar F. F., Spitz M. R. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl. Cancer Inst. 2002; 94(9)681–689
   PubMed Web of Science ®Google Scholar
• Matakidou A., Eisen T., Houlstoun R. S. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003; 18(4)377–385
   PubMed Web of Science ®Google Scholar
• Travis W. D., Brambilla E., Muller-Hermelink H. K., Harris C. C. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, LyonFrance 2004
   Google Scholar
• Sobin L. H., Wittekind C. TNM classification of malignant tumours, 6th ed. John Wiley & Sons, Hoboken, NJ 2002
   Google Scholar
• Hu Y., McDermott M. P., Ahrendt S. A. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin. Cancer Res. 2005; 11(7)2502–2509
   PubMed Web of Science ®Google Scholar
• Lazar V., Hazard F., Bertin F., Janin N., Bellet D., Bressac B. Simple sequence repeat polymorphism within the p53 gene. Oncogene 1993; 8(6)1703–1705
   PubMed Web of Science ®Google Scholar
• Sullivan A., Syed N., Gasco M., Bergamaschi D., Trigiante G., Attard M., Hiller L., Farrell P. J., Smith P., Lu X., Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23(19)3328–3337
   PubMed Web of Science ®Google Scholar
• Wang Y. C., Lee H. S., Chen S. K., Chang Y. Y., Chen C. Y. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur. J. Cancer 1999; 35(2)226–230
   PubMed Web of Science ®Google Scholar
• Starinsky S., Figer A., Ben-Asher E., Geva R., Flex D., Fidder H. H., Zidan J., Lancet D., Friedman E. Genotype phenotype correlations in Israeli colorectal cancer patients. Int. J. Cancer 2005; 114(1)58–73
   PubMed Web of Science ®Google Scholar
• Tommiska J., Eerola H., Heinonen M., Salonen L., Kaare M., Tallila J., Ristimäki A., von Smitten K., Aittomäki K., Heikkilä P., Blomqvist C., Nevanlinna H. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin. Cancer Res. 2005; 11(14)5098–5103
   PubMed Web of Science ®Google Scholar
• Tagawa M., Murata M., Kimura H. Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. Cancer Lett. 1998; 128(1)93–99
   PubMed Web of Science ®Google Scholar
• Matakidou A., el Galta R., Webb E. L., Rudd M. F., Bridle H., Eisen T., Houlston R. S. GELCAPS Consortium. Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: An analysis of survival in 619 female patients. Lung cancer 2007, in press
   PubMed Web of Science ®Google Scholar
• Thomas L., Doyle L. A., Edelman M. J. Lung cancer in women. Emerging differences in epidemiology, biology, and therapy. Chest 2005; 128(1)370–381
   Google Scholar